Abstract
We carried out a well-controlled study to evaluate the efficacy, safety, and usefulness of cefclidin (CFCL) in respiratory tract infections, using ceftazidime (CAZ) as the reference drug. Either CFCL or CAZ was given intravenously in a dose of 2 g daily (1 g b.i.d.) for 14 days as a rule. The following results were obtained: 1) The overall clinical efficacy rate assessed by attending physicians was 89.9% (62/69) for CFCL and 85.7% (72/84) for CAZ, and there was no statistically significant difference between the two agents. For moderate infections the efficacy rate and “excellent” response rate was significantly higher for CFCL than for CAZ (U-test, p<;0.05). In the judgment by the Efficacy Assessment Committee (Study Committee), the rates were 83.3% (60/70) for CFCL and 80.0% (68/85) for CAZ, with no statistically significant difference between the two agents. 2) With regard to bacteriological response, the eradication rate in monomicrobial infections was 91.2% (31/34) for CFCL and 69.2% (27/39) for CAZ (χ2-test, p<;0.05). The overall eradication rate was higher for CFCL than for CAZ, 90.5% (38/42) vs 72.5% (37/51). In particular, the eradication rate for Pseudomonas aeruginosa was 73.3% (11/15) for CFCL and 53.8% (14/26) for CAZ. 3) Adverse drug reactions were observed in 4.5% (4/89) in the CFCL group and 3.1% (3/96) in the CAZ group. The incidence of abnormal laboratory findings was judged by attending physicians to be 21.2% (18/85) in the CFCL group and 20.9% (19/91) in the CAZ group. The Study Committee rates were 23.5% (20/85) for CFCL and 26.4% (24/91) for CAZ. No severe symptoms or abnormal findings were observed, and there was no significant difference between the two drugs. 4) The usefulness rates judged by attending physicians were 88.4% (61/69) for CFCL and 82.1% (69/84) for CAZ (U-test, p<;0.05). The usefulness rates according to the Study Committee were 80.6% (58/72) for CFCL and 77.9% (67/86) for CAZ, with no significant difference. Based on the above results, it was concluded that CFCL is useful from the viewpoint of efficacy and safety in the treatment of respiratory tract infections. Since CFCL exhibits a potent in vitro activity and a high eradication rate against P. aeruginosa, it appears that this drug is likely to be useful in the treatment of refractory Pseudomonas respiratory infections.
| Original language | English |
|---|---|
| Pages (from-to) | 104-127 |
| Number of pages | 24 |
| Journal | Chemotherapy |
| Volume | 41 |
| Issue number | 1 |
| DOIs | |
| Publication status | Published - 1993 |
| Externally published | Yes |
Fingerprint
ASJC Scopus subject areas
- Oncology
- Pharmacology
- Drug Discovery
- Pharmacology (medical)
- Infectious Diseases
Cite this
A comparative study of cefclidin and ceftazidime in chronic respiratory tract infections. / Hara, Kohei; Kohno, Shigeru; Koga, Hironobu; Saito, Akira; Ohmichi, Mitsuhide; Hiraga, Yohmei; Takebe, Kazuo; Yoshida, Tsukasa; Ito, Toshiharu; Watanabe, Akira; Sato, Kazuo; Onuma, Kikuo; Katsu, Masataka; Ohishi, Akira; Kabe, Junzaburo; Arioka, Hitoshi; Nakajima, Noriko; Yoshizawa, Atsuhito; Nakata, Koichiro; Nakamori, Yoshitaka; Nakatani, Tatsuo; Narui, Kohji; Tsuboi, Eiyasu; Shimada, Kaoru; Goto, Hajime; Inamatsu, Takashi; Kodaira, Makoto; Masuda, Yoshishige; Sano, Yasuyuki; Koshino, Ken; Arai, Yasuo; Shimadaand, Jingoro; Yoshida, Masaki; Tanimoto, Hiroichi; Kobayashi, Hiroyuki; Inoue, Hisashi; Koyama, Masaru; Odagiri, Shigeki; Matsumura, Masanori; Suzuki, Kaneo; Ashikari, Yasuhiko; Shoji, Akira; Arakawa, Masaaki; Wada, Kouichi; Kawashima, Takashi; Takatoh, Masanaga; Hoshino, Shigeyuki; Iwata, Fumihide; Osaki, Naoki; Shimazu, Yoshinori; Sekine, Osamu; Suzuki, Yasutoshi; Aoki, Nobuki; Izumi, Saburo; Kishimoto, Susumu; Masuno, Tomiya; Hayashi, Seiji; Tsubura, Eiro; Nakagawa, Masaru; Igarashi, Tsuyoshi; Komuta, Kiyoshi; Sakatani, Mitsunori; Ogawara, Mitsumasa; Ochi, Norio; Itakura, Norio; Ito, Masami; Kojiro, Naoyoshi; Ikeda, Toshiyuki; Yoshimoto, Takahiko; Hara, Hideki; Kumagai, Toru; Miki, Fumio; Narita, Nobuhiro; Sawaki, Masayoshi; Mikasa, Keiichi; Soejima, Rinzo; Sumi, Masaru; Matsushima, Toshiharu; Kimura, Makoto; Sasaki, Takao; Matsumoto, Yukio; Sugimoto, Yuji; Yamakido, Michio; Hasegawa, Kenji; Sadamoto, Kenichiro; Kuwabara, Masao; Nishimoto, Yukio; Yanagida, Jitsuo; Yukutake, Masato; Awaya, Yukikazu; Kurimura, Osamu; Sasaki, Hideo; Oune, Akimasa; Muranishi, Hisakazu; Miyazaki, Masayuki; Oizumi, Kotaro; Ichikawa, Yoichiro; Tokunaga, Hisato; Nasu, Masaru; Matsumoto, Keizo; Takahashi, Atsushi; Tanaka, Hirofumi; Taguchi, Mikio; Shishido, Harumi; Nagai, Hideaki; Sato, Koji; Kurashima, Atsuyuki; Shima, Kiyoshi; Takenaka, Shinobu; Saito, Atsushi; Irabu, Yuei; Kusano, Nobuchika; Wakuta, Moriaki; Ogawa, Nobuya; Yamaguchi, Keizo; Kaku, Mitsuo; Sugawara, Kazuyuki.
In: Chemotherapy, Vol. 41, No. 1, 1993, p. 104-127.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - A comparative study of cefclidin and ceftazidime in chronic respiratory tract infections
AU - Hara, Kohei
AU - Kohno, Shigeru
AU - Koga, Hironobu
AU - Saito, Akira
AU - Ohmichi, Mitsuhide
AU - Hiraga, Yohmei
AU - Takebe, Kazuo
AU - Yoshida, Tsukasa
AU - Ito, Toshiharu
AU - Watanabe, Akira
AU - Sato, Kazuo
AU - Onuma, Kikuo
AU - Katsu, Masataka
AU - Ohishi, Akira
AU - Kabe, Junzaburo
AU - Arioka, Hitoshi
AU - Nakajima, Noriko
AU - Yoshizawa, Atsuhito
AU - Nakata, Koichiro
AU - Nakamori, Yoshitaka
AU - Nakatani, Tatsuo
AU - Narui, Kohji
AU - Tsuboi, Eiyasu
AU - Shimada, Kaoru
AU - Goto, Hajime
AU - Inamatsu, Takashi
AU - Kodaira, Makoto
AU - Masuda, Yoshishige
AU - Sano, Yasuyuki
AU - Koshino, Ken
AU - Arai, Yasuo
AU - Shimadaand, Jingoro
AU - Yoshida, Masaki
AU - Tanimoto, Hiroichi
AU - Kobayashi, Hiroyuki
AU - Inoue, Hisashi
AU - Koyama, Masaru
AU - Odagiri, Shigeki
AU - Matsumura, Masanori
AU - Suzuki, Kaneo
AU - Ashikari, Yasuhiko
AU - Shoji, Akira
AU - Arakawa, Masaaki
AU - Wada, Kouichi
AU - Kawashima, Takashi
AU - Takatoh, Masanaga
AU - Hoshino, Shigeyuki
AU - Iwata, Fumihide
AU - Osaki, Naoki
AU - Shimazu, Yoshinori
AU - Sekine, Osamu
AU - Suzuki, Yasutoshi
AU - Aoki, Nobuki
AU - Izumi, Saburo
AU - Kishimoto, Susumu
AU - Masuno, Tomiya
AU - Hayashi, Seiji
AU - Tsubura, Eiro
AU - Nakagawa, Masaru
AU - Igarashi, Tsuyoshi
AU - Komuta, Kiyoshi
AU - Sakatani, Mitsunori
AU - Ogawara, Mitsumasa
AU - Ochi, Norio
AU - Itakura, Norio
AU - Ito, Masami
AU - Kojiro, Naoyoshi
AU - Ikeda, Toshiyuki
AU - Yoshimoto, Takahiko
AU - Hara, Hideki
AU - Kumagai, Toru
AU - Miki, Fumio
AU - Narita, Nobuhiro
AU - Sawaki, Masayoshi
AU - Mikasa, Keiichi
AU - Soejima, Rinzo
AU - Sumi, Masaru
AU - Matsushima, Toshiharu
AU - Kimura, Makoto
AU - Sasaki, Takao
AU - Matsumoto, Yukio
AU - Sugimoto, Yuji
AU - Yamakido, Michio
AU - Hasegawa, Kenji
AU - Sadamoto, Kenichiro
AU - Kuwabara, Masao
AU - Nishimoto, Yukio
AU - Yanagida, Jitsuo
AU - Yukutake, Masato
AU - Awaya, Yukikazu
AU - Kurimura, Osamu
AU - Sasaki, Hideo
AU - Oune, Akimasa
AU - Muranishi, Hisakazu
AU - Miyazaki, Masayuki
AU - Oizumi, Kotaro
AU - Ichikawa, Yoichiro
AU - Tokunaga, Hisato
AU - Nasu, Masaru
AU - Matsumoto, Keizo
AU - Takahashi, Atsushi
AU - Tanaka, Hirofumi
AU - Taguchi, Mikio
AU - Shishido, Harumi
AU - Nagai, Hideaki
AU - Sato, Koji
AU - Kurashima, Atsuyuki
AU - Shima, Kiyoshi
AU - Takenaka, Shinobu
AU - Saito, Atsushi
AU - Irabu, Yuei
AU - Kusano, Nobuchika
AU - Wakuta, Moriaki
AU - Ogawa, Nobuya
AU - Yamaguchi, Keizo
AU - Kaku, Mitsuo
AU - Sugawara, Kazuyuki
PY - 1993
Y1 - 1993
N2 - We carried out a well-controlled study to evaluate the efficacy, safety, and usefulness of cefclidin (CFCL) in respiratory tract infections, using ceftazidime (CAZ) as the reference drug. Either CFCL or CAZ was given intravenously in a dose of 2 g daily (1 g b.i.d.) for 14 days as a rule. The following results were obtained: 1) The overall clinical efficacy rate assessed by attending physicians was 89.9% (62/69) for CFCL and 85.7% (72/84) for CAZ, and there was no statistically significant difference between the two agents. For moderate infections the efficacy rate and “excellent” response rate was significantly higher for CFCL than for CAZ (U-test, p<;0.05). In the judgment by the Efficacy Assessment Committee (Study Committee), the rates were 83.3% (60/70) for CFCL and 80.0% (68/85) for CAZ, with no statistically significant difference between the two agents. 2) With regard to bacteriological response, the eradication rate in monomicrobial infections was 91.2% (31/34) for CFCL and 69.2% (27/39) for CAZ (χ2-test, p<;0.05). The overall eradication rate was higher for CFCL than for CAZ, 90.5% (38/42) vs 72.5% (37/51). In particular, the eradication rate for Pseudomonas aeruginosa was 73.3% (11/15) for CFCL and 53.8% (14/26) for CAZ. 3) Adverse drug reactions were observed in 4.5% (4/89) in the CFCL group and 3.1% (3/96) in the CAZ group. The incidence of abnormal laboratory findings was judged by attending physicians to be 21.2% (18/85) in the CFCL group and 20.9% (19/91) in the CAZ group. The Study Committee rates were 23.5% (20/85) for CFCL and 26.4% (24/91) for CAZ. No severe symptoms or abnormal findings were observed, and there was no significant difference between the two drugs. 4) The usefulness rates judged by attending physicians were 88.4% (61/69) for CFCL and 82.1% (69/84) for CAZ (U-test, p<;0.05). The usefulness rates according to the Study Committee were 80.6% (58/72) for CFCL and 77.9% (67/86) for CAZ, with no significant difference. Based on the above results, it was concluded that CFCL is useful from the viewpoint of efficacy and safety in the treatment of respiratory tract infections. Since CFCL exhibits a potent in vitro activity and a high eradication rate against P. aeruginosa, it appears that this drug is likely to be useful in the treatment of refractory Pseudomonas respiratory infections.
AB - We carried out a well-controlled study to evaluate the efficacy, safety, and usefulness of cefclidin (CFCL) in respiratory tract infections, using ceftazidime (CAZ) as the reference drug. Either CFCL or CAZ was given intravenously in a dose of 2 g daily (1 g b.i.d.) for 14 days as a rule. The following results were obtained: 1) The overall clinical efficacy rate assessed by attending physicians was 89.9% (62/69) for CFCL and 85.7% (72/84) for CAZ, and there was no statistically significant difference between the two agents. For moderate infections the efficacy rate and “excellent” response rate was significantly higher for CFCL than for CAZ (U-test, p<;0.05). In the judgment by the Efficacy Assessment Committee (Study Committee), the rates were 83.3% (60/70) for CFCL and 80.0% (68/85) for CAZ, with no statistically significant difference between the two agents. 2) With regard to bacteriological response, the eradication rate in monomicrobial infections was 91.2% (31/34) for CFCL and 69.2% (27/39) for CAZ (χ2-test, p<;0.05). The overall eradication rate was higher for CFCL than for CAZ, 90.5% (38/42) vs 72.5% (37/51). In particular, the eradication rate for Pseudomonas aeruginosa was 73.3% (11/15) for CFCL and 53.8% (14/26) for CAZ. 3) Adverse drug reactions were observed in 4.5% (4/89) in the CFCL group and 3.1% (3/96) in the CAZ group. The incidence of abnormal laboratory findings was judged by attending physicians to be 21.2% (18/85) in the CFCL group and 20.9% (19/91) in the CAZ group. The Study Committee rates were 23.5% (20/85) for CFCL and 26.4% (24/91) for CAZ. No severe symptoms or abnormal findings were observed, and there was no significant difference between the two drugs. 4) The usefulness rates judged by attending physicians were 88.4% (61/69) for CFCL and 82.1% (69/84) for CAZ (U-test, p<;0.05). The usefulness rates according to the Study Committee were 80.6% (58/72) for CFCL and 77.9% (67/86) for CAZ, with no significant difference. Based on the above results, it was concluded that CFCL is useful from the viewpoint of efficacy and safety in the treatment of respiratory tract infections. Since CFCL exhibits a potent in vitro activity and a high eradication rate against P. aeruginosa, it appears that this drug is likely to be useful in the treatment of refractory Pseudomonas respiratory infections.
UR - http://www.scopus.com/inward/record.url?scp=0027462741&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0027462741&partnerID=8YFLogxK
U2 - 10.11250/chemotherapy1953.41.104
DO - 10.11250/chemotherapy1953.41.104
M3 - Article
AN - SCOPUS:0027462741
VL - 41
SP - 104
EP - 127
JO - Chemotherapy
JF - Chemotherapy
SN - 0009-3165
IS - 1
ER -